Zheng H - Search Results

1

Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment.

Peng H, Wu X, Liu S, He M, Xie C, Zhong R, Liu J, Tang C, Li C, Xiong S, Zheng H, He J, Lu X, Liang W. Peng H, et al. Among authors: zheng h. Clin Transl Med. 2023 Jan;13(1):e1155. doi: 10.1002/ctm2.1155. Clin Transl Med. 2023. PMID: 36588094 Free PMC article.

2

Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence.

Peng H, Wu X, Zhong R, Yu T, Cai X, Liu J, Wen Y, Ao Y, Chen J, Li Y, He M, Li C, Zheng H, Chen Y, Pan Z, He J, Liang W. Peng H, et al. Among authors: zheng h. Front Immunol. 2021 Nov 4;12:750046. doi: 10.3389/fimmu.2021.750046. eCollection 2021. Front Immunol. 2021. PMID: 34804034 Free PMC article.

3

Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).

Li M, Hou X, Sai K, Wu L, Chen J, Zhang B, Wang N, Wu L, Zheng H, Zhang J, Mou Y, Chen L. Li M, et al. Among authors: zheng h. Oncoimmunology. 2022 Mar 31;11(1):2059874. doi: 10.1080/2162402X.2022.2059874. eCollection 2022. Oncoimmunology. 2022. PMID: 35402080 Free PMC article.

4

Macrophages-based immune-related risk score model for relapse prediction in stage I-III non-small cell lung cancer assessed by multiplex immunofluorescence.

Wu XR, Peng HX, He M, Zhong R, Liu J, Wen YK, Li CC, Li JF, Xiong S, Yu T, Zheng HB, Chen YH, He JX, Liang WH, Cai XY. Wu XR, et al. Transl Lung Cancer Res. 2022 Apr;11(4):523-542. doi: 10.21037/tlcr-21-916. Transl Lung Cancer Res. 2022. PMID: 35529784 Free PMC article.

5

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.

Zhong YM, Yin K, Chen Y, Xie Z, Lv ZY, Yang JJ, Yang XN, Zhou Q, Wang BC, Zhong WZ, Gao LL, Zhou WB, Chen J, Tu HY, Liao RQ, Zhang DK, Zhang SL, Lu DX, Zheng HB, Zhang HH, Wu YL, Zhang XC. Zhong YM, et al. Front Immunol. 2022 Oct 3;13:951817. doi: 10.3389/fimmu.2022.951817. eCollection 2022. Front Immunol. 2022. PMID: 36263036 Free PMC article.

6

Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil.

Peng H, Wu X, Liu S, He M, Tang C, Wen Y, Xie C, Zhong R, Li C, Xiong S, Liu J, Zheng H, He J, Lu X, Liang W. Peng H, et al. Among authors: zheng h. Clin Transl Med. 2023 Jul;13(7):e1340. doi: 10.1002/ctm2.1340. Clin Transl Med. 2023. PMID: 37491740 Free PMC article.

7

The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.

Cheng B, Li C, Li J, Gong L, Liang P, Chen Y, Zhan S, Xiong S, Zhong R, Liang H, Feng Y, Wang R, Wang H, Zheng H, Liu J, Zhou C, Shao W, Qiu Y, Sun J, Xie Z, Liang Z, Yang C, Cai X, Su C, Wang W, He J, Liang W. Cheng B, et al. Among authors: zheng h. Signal Transduct Target Ther. 2024 Apr 19;9(1):93. doi: 10.1038/s41392-024-01799-z. Signal Transduct Target Ther. 2024. PMID: 38637495 Free PMC article. Clinical Trial.

8

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.

Li L, Lu G, Liu Y, Gong L, Zheng X, Zheng H, Gu W, Yang L. Li L, et al. Among authors: zheng x, zheng h. Front Oncol. 2021 Jun 4;11:658690. doi: 10.3389/fonc.2021.658690. eCollection 2021. Front Oncol. 2021. PMID: 34150625 Free PMC article.

9

Dissecting the genetic variations associated with response to first-line chemotherapy in patients with small cell lung cancer: a retrospective cohort study.

Zhang Y, Hao Y, Pan H, Zheng H, Zhou J. Zhang Y, et al. Among authors: zheng h. J Thorac Dis. 2023 Dec 30;15(12):7013-7023. doi: 10.21037/jtd-23-1772. Epub 2023 Dec 26. J Thorac Dis. 2023. PMID: 38249933 Free PMC article.

10

Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer.

Li J, Hu H, Qin G, Bai F, Wu X, Ke H, Zhang J, Xie Y, Wu Z, Fu Y, Zheng H, Gong L, Xie Z, Deng Y. Li J, et al. Among authors: zheng h. Clin Cancer Res. 2024 Jan 17;30(2):368-378. doi: 10.1158/1078-0432.CCR-23-2213. Clin Cancer Res. 2024. PMID: 37906636

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16,713 results

Search Page